Cita APA

Giné Soca, E., de la Cruz, F., Jimenez-Ubieto, A., Terol, M. J., Marin Niebla, A., Martín García-Sancho, A., & Lopez-Jimenez, J. (2022). Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Citación estilo Chicago

Giné Soca, Eva, Fatima de la Cruz, Ana Jimenez-Ubieto, M. Jose Terol, Ana Marin Niebla, Alejandro Martín García-Sancho, y Javier Lopez-Jimenez. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. 2022.

Cita MLA

Giné Soca, Eva, et al. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. 2022.